...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution
【24h】

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution

机译:结节性淋巴细胞为主的霍奇金淋巴瘤中的大B细胞转化:来自单一机构的40年经验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A number of reports have shown a propensity of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) to transform into diffuse large B-cell lymphoma (DLBCL). Long-term data on the incidence and outcomes of transformed NLPHL are lacking. A comprehensive analysis of the actively maintained Mayo Clinic Lymphoma Database was performed. Between 1970 and 2011, 222 consecutive adult patients with new untreated NLPHL were identified. Median age at diagnosis was 40 years, and 146 (66%) were males. The median follow-up was 16 years. Seventeen patients (7.6%) developed a transformation to DLBCL. The median time to transformation was 35 months (range, 6-268 months). Based on the observed 17 transformations during 2304 patient-years of followup, the rate of transformation was 0.74 per 100 patient-years. In a multivariate analysis, use of any prior chemotherapy (P = .04) and splenic involvement (P = .03) were significantly associated with increased risk of transformation. The 5-year overall survival (OS) in those with transformed disease was 76.4%, and transformation did not adversely affect OS when compared with patients who did not experience transformation. In this large single-institution cohort with long-term follow-up, the risk of transformation was lower than that observed in other low-grade lymphomas.
机译:许多报告显示,结节性淋巴细胞为主的霍奇金淋巴瘤(NLPHL)倾向于转变为弥漫性大B细胞淋巴瘤(DLBCL)。缺乏有关转化的NLPHL发生率和预后的长期数据。对积极维护的梅奥诊所淋巴瘤数据库进行了全面分析。在1970年至2011年之间,确定了222例连续的成年患者,他们接受了新的未经治疗的NLPHL。诊断时的中位年龄为40岁,男性为146位(66%)。中位随访时间为16年。 17名患者(7.6%)转变为DLBCL。转化的中位数时间为35个月(范围为6-268个月)。根据在2304个患者-年的随访期间观察到的17个转化,转化率为每100个患者-年0.74。在多变量分析中,以前使用过的任何化疗(P = .04)和脾脏受累(P = .03)与转化风险增加显着相关。患有转化疾病的患者的5年总生存(OS)为76.4%,与未经历转化的患者相比,转化对OS没有不利影响。在具有长期随访的大型单机构队列中,发生转化的风险低于在其他低度淋巴瘤中观察到的风险。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号